|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Stent or surgery for incurable obstructive colorectal cancer: an individualized decisión显示文摘 | Javier Súarez Javier Jiménez Ruth Vera Antonio Tarifa Enrique Balén Virginia Arrazubi Juan Vila Jose M. Lera | 2010 | International Journal of Colorectal Disease2010，，1： | 1 |
| 2 | Stent or surgery for incurable obstructive colorectal cancer: an individualized decisión显示文摘 | Javier Súarez Javier Jiménez Ruth Vera Antonio Tarifa Enrique Balén Virginia Arrazubi Juan Vila Jose M. Lera | 2010 | International Journal of Colorectal Disease2010，，1： | 1 |
| 3 | The EORTC cancer in- patient satisfaction with care questionnaire EORTC INPAT - SAT32 validation study for spanish patients 显示文摘 | Juan Ignaeio Arraras Ruth Vera Maite Martinez ct al | 2009 | Clin Transl Oneol2009，11，： | 1 |
| 4 | New material for orthopedic implants:Electrochemical study of nickel free P558stainless steel in minimum essential medium显示文摘 | Ruth Flavia Vera Villamil Jaimesa Mónica Luisa Chaves de Andrade Afonsob Sizue Otta Rogeroc | 2010 | Mater Lett2010，64，13： | 1 |
| 5 | Stent or surgery for incurable obstruction colorectal cancer: an individual decision 显示文摘 | Javier Suarez Javier Jimenez Ruth Vera | 2010 | Int J Colorectal Dis2010，25，： | 1 |
| 6 | Evaluation of the prognotic significance of cathepsin D, epidermal growth factor receptor, and C-erbB-2 in early cervical squamous cell carcinoma显示文摘 | Gunnar BK Ruth H Vera MA | 1996 | Cancer1996，78，3： | 1 |
| 7 | Structural basis of sympathetic-sensory coupling in rat and human dorsal root ganglia following peripheral nerve injury显示文摘 | Vera Shinder Ruth Govrin-Lippmann Shulamith Cohen Michael Belenky Polina Ilin Kaj Fried Harold A. Wilkinson Marshall Devor | 1999 | Journal of Neurocytology1999，，9： | 1 |
| 8 | Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma显示文摘 | Kuan-Ting Kuo Tsui-Lien Mao Sian Jones Emanuela Veras Ayse Ayhan Tian-Li Wang Ruth Glas Dennis Slamon Victor E. Velculescu Robert J. Kuman Ie-Ming Shih | 2009 | The American Journal of Pathology2009，，5： | 1 |
| 9 | The intracellular signalosome of PD-L1 in cancer cells显示文摘Programmed cell death-1 ligand-1(PD-L1)overexpression in cancer cells accelerates tumor progression.PD-L1 possesses two main pro-oncogenic functions.First,PD-L1 is a strong immunosuppressive molecule that inactivates tumor-specific T cells by binding to the inhibitory receptor PD-1.Second,PD-L1 function relies on the delivery of intrinsic intracellular signals that enhance cancer cell survival,regulate stress responses and confer resistance toward pro-apoptotic stimuli,such as interferons.Here,we review the current knowledge on intracellular signal transduction pathways regulated by PD-L1,describe its associated signalosome and discuss potential combinations of targeted therapies against the signalosome with PD-L1/PD-1 blockade therapies. | David Escors Maria Gato-Canas Miren Zuazo Hugo Arasanz María Jesus García-Granda Ruth Vera Grazyna Kochan | 2018 | Signal Transduction and Targeted Therapy2018，3，1： | 0 |
| 10 | Integration of molecular testing for the personalized management of patients with diffuse large B-cell lymphoma and follicular lymphoma显示文摘Diffuse large B-cell lymphoma(DLBCL)and follicular lymphoma(FL)are the most common forms of aggressive and indolent lymphoma,respectively.The majority of patients are cured by standard R-CHOP immunochemotherapy,but 30%–40%of DLBCL and 20%of FL patients relapse or are refractory(R/R).DLBCL and FL are phenotypically and genetically hereterogenous B-cell neoplasms.To date,the diagnosis of DLBCL and FL has been based on morphology,immunophenotyping and cytogenetics.However,next-generation sequencing(NGS)is widening our understanding of the genetic basis of the B-cell lymphomas.In this review we will discuss how integrating the NGS-based characterization of somatic gene mutations with diagnostic or prognostic value in DLBCL and FL could help refine B-cell lymphoma classification as part of a multidisciplinary pathology work-up.We will also discuss how molecular testing can identify candidates for clinical trials with targeted therapies and help predict therapeutic outcome to currently available treatments,including chimeric antigen receptor T-cell,as well as explore the application of circulating cell-free DNA,a non-invasive method for patient monitoring.We conclude that molecular analyses can drive improvements in patient outcomes due to an increased understanding of the different pathogenic pathways affected by each DLBCL subtype and indolent FL vs R/R FL. | Ruth Stuckey Hugo Luzardo Henríquez Haridian de la Nuez Melian JoséCarlos Rivero Vera Cristina Bilbao-Sieyro María Teresa Gómez-Casares | 2023 | World Journal of Clinical Oncology2023，14，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员